Progress in molecular-based management of differentiated thyroid cancer
about
Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid CancerGenetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical ImplicationsTreatment strategies for radioactive iodine-refractory differentiated thyroid cancerHighly prevalent TERT promoter mutations in aggressive thyroid cancers.Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to VemurafenibBRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrenceDiagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.A new model for reimbursing genome-based cancer careSASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerDevelopment and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology GroupSodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancerIntegrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.Genetic epidemiology: the potential benefits and challenges of using genetic information to improve human health.Application of molecular diagnostics to the evaluation of the surgical approach to thyroid cancerAnterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells.New insights in risk stratification of differentiated thyroid cancer.The pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma.How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodiesRUNX3 site-specific hypermethylation predicts papillary thyroid cancer recurrence.Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.Molecular profiling of thyroid cancer subtypes using large-scale text mining.Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancerSorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialLaser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience.BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysisApplication of metabolomics in thyroid cancer research.The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.The variable phenotype and low-risk nature of RAS-positive thyroid nodules.Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis.Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer.The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genesA loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability.Expression profiles of pivotal microRNAs and targets in thyroid papillary carcinoma: an analysis of The Cancer Genome Atlas.Zn(II)-curc targets p53 in thyroid cancer cellsDrosophila Cancer Models Identify Functional Differences between Ret Fusions.Novel and Practical Scoring Systems for the Diagnosis of Thyroid NodulesThe discovery and development of sorafenib for the treatment of thyroid cancer.Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules
P2860
Q26744936-52FCA696-3909-40A4-94BD-2996C116BD2CQ26765085-1244D1F0-B8A4-4F6E-A2C3-D016CC8B189CQ26862841-EA536B10-0D17-40A7-8847-4D118C3C2D6FQ27852353-CFDB38D7-E094-4B73-A761-ABAFE52C5A04Q27853034-4B467504-CFA7-4644-BBE5-834676238EABQ27853042-D9DE107F-E113-4D40-A51A-54949E56A3BAQ27853057-7C22D9D1-472E-4635-9FEB-0CACCBD66029Q28660087-E0250DD1-EB3D-4410-8F6B-2B5FCF7BC057Q30009047-773DFE72-020E-44D1-B591-648A91269839Q30367068-7BC0CE3A-F7BB-4AF6-8EB0-6E2CD5F810CEQ33570096-B074CA8A-E461-4A20-B1C0-E61096C42419Q33587905-F20C0F58-FE7A-4A34-A641-9552039E1D8BQ33603806-820200FC-44B4-4285-8018-9A0845465F53Q33629836-D1B862BD-26F9-47D5-80C1-8DB0CE4C29A2Q33698750-D1015F16-1B3B-4F26-8C67-4C5D54BAA85FQ33782121-151636AB-8714-43CF-ADD4-242CE34E77D2Q33890655-DC8E6268-CDB7-40AC-AEFD-3C8873C75095Q33915384-C5ED3EDC-902D-44C3-B54B-E782F3959107Q33973108-D8AC2649-22D8-46EC-A338-3005FC791062Q34134307-AE4B58E7-A446-46F4-B87C-A91CC1477969Q34704862-995CA14C-D188-49F8-A7B8-0E8AFAA6781CQ34716574-F9B7B0CC-0835-4655-B5C5-43A9C18480E6Q34914970-01A4EB61-98BD-4458-8187-E9817EE11CB1Q35064835-742C3773-E99D-48CB-A9B9-410B3A0743F6Q35195766-8DA1DC63-4C1F-4D10-850B-A25C9E47682AQ35501424-C486AFE6-A527-46AB-AC3C-19D5727BDE10Q35543644-A28CDBC5-A5A8-4AA0-B62F-FB742B904825Q35564078-6666C930-B7E2-44DA-86EE-1606AF20FC3DQ35692478-0A12BC09-1B42-4F9C-994D-FF6C00BCDBFBQ35740151-34713C47-3243-46DA-8901-B15ADFEE3409Q35793689-C2805DEC-05A3-451D-9729-8CC740128EDDQ35906046-70C4C48B-F522-49A6-9FEA-B8A290E0C321Q35906347-BDD0B387-4FE7-41B6-8185-3D7477E78B28Q35983871-53AF1FEC-3B75-4A39-9CE1-876D726BE1ADQ36015168-98423504-814B-4296-96D9-4F508E703605Q36094135-249D5594-4AEC-4BAB-9BAF-788D2E6FB41AQ36132331-0F3B932D-991A-4B33-A4FC-E92C89EC8D7CQ36139842-3B75152D-14AD-4F9A-BFFF-A88161AD851DQ36263304-B731033A-DB93-497A-9638-B2D785C8AC8DQ36310205-AF594829-CB88-4ECE-881C-7A9E94017C77
P2860
Progress in molecular-based management of differentiated thyroid cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Progress in molecular-based management of differentiated thyroid cancer
@ast
Progress in molecular-based management of differentiated thyroid cancer
@en
Progress in molecular-based management of differentiated thyroid cancer
@nl
type
label
Progress in molecular-based management of differentiated thyroid cancer
@ast
Progress in molecular-based management of differentiated thyroid cancer
@en
Progress in molecular-based management of differentiated thyroid cancer
@nl
prefLabel
Progress in molecular-based management of differentiated thyroid cancer
@ast
Progress in molecular-based management of differentiated thyroid cancer
@en
Progress in molecular-based management of differentiated thyroid cancer
@nl
P2093
P2860
P3181
P1433
P1476
Progress in molecular-based management of differentiated thyroid cancer
@en
P2093
Bryan R Haugen
Martin Schlumberger
Mingzhao Xing
P2860
P304
P3181
P356
10.1016/S0140-6736(13)60109-9
P407
P577
2013-03-23T00:00:00Z